Riva

Riva Therapeutics is a precision oncology company dedicated to developing next-generation therapeutics targeting the DNA damage response (DDR) pathway. The company leverages a proprietary platform to identify and validate novel synthetic lethal interactions, aiming to treat cancers with specific genetic vulnerabilities. Founded by industry veterans, Riva focuses on small molecule inhibitors that can overcome resistance to current DDR therapies. Their approach integrates advanced computational biology with deep mechanistic insights to build a robust pipeline of oncology candidates. Headquartered in South San Francisco, the firm is backed by leading venture capital firms such as OrbiMed and F-Prime Capital.